炎症性肠道疾病患者的皮下vedolizumab间隔延长:一个案例系列
Suzanne I Anjie1, Krisztina B Gecse1, Cyriel Y Ponsioen1
1Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
Therapeutic advances in gastroenterology
|February 26, 2024
概括
在缓解期的炎症性肠病 (IBD) 患者中延长皮下vedolizumab注射间隔是安全有效的. 这种方法可以减少副作用和医疗保健成本.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮下注射的vedolizumab在炎症性肠病 (IBD) 维持治疗中是有效的.
- 关于延长皮下注射vedolizumab注射间隔的数据有限.
- 需要对间隔延长进行现实世界的证据.
研究的目的:
- 评估在IBD患者中延长皮下vedolizumab注射间隔的疗效和安全性.
- 评估间隔延长后的临床,生化和药物度变化.
- 为了确定对视多利祖马布相关副作用的影响.
主要方法:
- 对9名IBD患者 (8名克罗恩氏病,1名性结肠炎) 的回顾性分析.
- 临床和生化缓解期的患者每2周一次的皮下 vedolizumab 延长至3,4或5周的间隔.
- 随访包括疾病爆发的评估,生化标志物,韦多利祖马布血清度和副作用.
主要成果:
- 在中位数为10.0个月的随访期间没有观察到疾病爆发.
- 生物化学参数 (便calprotectin,C反应蛋白) 保持稳定.
- 在间隔延长后,vedolizumab血清度显著下降 (p=0.018).
- 大多数疑似维多利祖马布诱导的副作用在6个月内消失.
结论:
- 延长皮下vedolizumab间隔对于IBD患者在缓解期是有效和安全的.
- 这种策略可以通过减少副作用来改善患者的耐受性.
- 间隔延长可能会导致医疗保健成本大幅降低.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334


